相关实验视频

Updated: Jun 26, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

优化免疫检查点抑制剂治疗计划,治疗复发性或耐火性外节NK/T细胞淋巴瘤

Sang Eun Yoon¹, Hyungwoo Cho², Philipp Berning³

¹Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Annals of hematology

|May 10, 2024

概括

布罗利祖马布在复发性/耐火性外性NK/T细胞淋巴瘤 (R/R ENKTL) 中表现有前途. 完成24个布罗利祖马布 (抗PD-L1) 周期显著改善了响应患者的无进展生存率.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
血液学血液学血液学

背景情况:

外节NK/T细胞淋巴瘤 (ENKTL) 是一种侵略性的非霍奇金淋巴瘤.
复发性/耐药性 (R/R) ENKTL的治疗选择有限,需要新的救援疗法.
布罗利祖马布是一种抗编程细胞死亡配体1 (PD-L1) 抑制剂,目前正在研究R/R ENKTL.

研究的目的:

在R/R ENKTL.中评估 pembrolizumab 治疗的最佳持续时间.
确定指导布罗利祖马布治疗中断或延续的临床因素.
评估pembrolizumab在R/R ENKTL患者中的疗效.

主要方法:

对58名R/R ENKTL患者的回顾性分析,这些患者接受了 pembrolizumab治疗.
每3个月使用18F-氧葡萄糖正子发射断层扫描/计算机断层扫描 (FDG PET/CT) 和爱斯坦巴尔病毒DNA (EBV DNA) 监测治疗结果.
基于Deaville分数 (DS) 和EBV状态的风险分层.

主要成果:

布罗利祖马布的整体响应率为38.9% (31.5%的完整响应).
无进展生存时间 (PFS) 中位数为3.1个月,总生存时间 (OS) 中位数为7.1个月.
与周期不完整的患者相比,完成24个计划周期的 pembrolizumab 患者的 PFS 显著改善 (57.6 个月 vs 20.9 个月).

结论:

布罗利祖马布是R / R ENKTL的可行的救援选择,最佳持续时间可能超过响应者24个周期.
对PET-CT和EBV的监测对于指导治疗决策至关重要.
低风险患者 (DS 1-2,EBV阴性) 可能受益于停止治疗,而高风险患者可能需要继续治疗.

关键词:

爱斯坦-巴尔病毒病毒.免疫检查点抑制剂免疫检查点抑制剂这就是Pembrolizumab.复发/耐药的外节 NK/T 细胞淋巴瘤.

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...